Printed on 3/17/2026
For informational purposes only. This is not medical advice.
The Revised Geneva Score is a validated clinical prediction rule for estimating the pretest probability of pulmonary embolism. Unlike the Wells PE score, it uses only objective variables, reducing inter-observer variability. Scores classify patients into low, intermediate, or high probability categories to guide D-dimer testing and imaging.
Formula: Age>65 (1) + Previous VTE (3) + Surgery (2) + Cancer (2) + Unilateral pain (3) + Palpation pain (4) + HR 75-94 (3) / HR≥95 (5) + Hemoptysis (2) + Edema (4).
When a patient presents with symptoms concerning for pulmonary embolism (chest pain, dyspnea, hemoptysis, tachycardia), the Revised Geneva Score provides a structured, entirely objective approach to estimating pretest probability. Unlike the Wells PE score, which includes the subjective criterion 'PE is the most likely diagnosis,' the Revised Geneva uses ONLY objective variables, eliminating inter-observer variability and improving reproducibility across different clinicians and settings. Collect the following 10 variables systematically: (1) **Age >65 years** (1 point) — increasing age is an independent VTE risk factor. (2) **Previous DVT or PE** (3 points) — history of venous thromboembolism significantly raises recurrence risk. (3) **Surgery or lower limb fracture in the past month** (2 points) — recent immobilization or surgery is a major provoked VTE risk. (4) **Active malignancy** (2 points) — cancer, especially metastatic or undergoing chemotherapy, is a potent VTE risk factor. (5) **Unilateral lower limb pain** (3 points) — suggests concurrent DVT, which co-occurs in ~40% of PE cases. (6) **Pain on palpation of deep veins + unilateral edema** (4 points) — highly specific for DVT. (7) **Heart rate 75–94 bpm** (3 points) or **HR ≥95 bpm** (5 points) — tachycardia reflects hemodynamic stress from PE. (8) **Hemoptysis** (2 points) — classic PE symptom from pulmonary infarction. (9) **Unilateral edema** (4 points) — strongly suggests DVT. Document each variable clearly, as the sum of these objective findings drives the diagnostic pathway. The score ranges from 0 to 26 (though scores >15 are rare).
Sum all points from the 10 variables to obtain the total Revised Geneva Score. Classify the pretest probability of pulmonary embolism as follows: **0–3 points (LOW probability):** PE prevalence in this group is approximately 8–10%. The low probability category represents patients with minimal objective risk factors—typically younger patients (<65), no prior VTE, no recent surgery or cancer, normal heart rate, and no DVT symptoms. In validation studies, only ~8% of low-probability patients had PE on CTPA. **4–10 points (INTERMEDIATE probability):** PE prevalence is approximately 25–30%. This is the largest and most heterogeneous category, including patients with one or two moderate risk factors (e.g., age >65 + tachycardia, or prior VTE alone, or active cancer + unilateral pain). About one-quarter to one-third of intermediate-probability patients have PE. **≥11 points (HIGH probability):** PE prevalence is approximately 60–75%. High-probability patients typically have multiple major risk factors: for example, active cancer (2 points) + prior VTE (3 points) + HR ≥95 (5 points) + unilateral edema (4 points) = 14 points. These patients have a very high likelihood of PE and should proceed directly to imaging. Some institutions use the simplified Geneva Score with different thresholds (0–1 low, 2–4 intermediate, ≥5 high), but the original Revised Geneva thresholds (0–3 / 4–10 / ≥11) are more widely validated and recommended by European Society of Cardiology (ESC) guidelines.
Apply the Revised Geneva Score to optimize the diagnostic workup and avoid unnecessary imaging. The evidence-based approach: **LOW probability (0–3):** Order D-dimer first. If D-dimer is NEGATIVE (<500 ng/mL or age-adjusted threshold), PE is effectively excluded—no further workup needed. Negative predictive value exceeds 99% when low probability + negative D-dimer. If D-dimer is POSITIVE, proceed to CT pulmonary angiography (CTPA). This strategy safely excludes PE in ~30–40% of suspected cases without radiation or contrast exposure. **INTERMEDIATE probability (4–10):** Also start with D-dimer. If NEGATIVE, PE is excluded (NPV ~98–99%). If POSITIVE, proceed to CTPA. However, be aware that D-dimer has lower specificity in intermediate-probability patients—many will have positive D-dimer from other causes (infection, inflammation, hospitalization, advanced age) and still require CTPA. **HIGH probability (≥11):** Proceed DIRECTLY to CTPA without D-dimer testing. In high-probability patients, D-dimer has insufficient negative predictive value to safely exclude PE (too many false negatives), and a positive D-dimer doesn't add information (you were already planning to image). Skipping D-dimer in high-probability patients avoids unnecessary delays—these patients need urgent diagnosis and treatment. Document the diagnostic pathway clearly: 'Revised Geneva Score = 2 (low probability). D-dimer ordered. If negative, PE excluded. If positive, will proceed with CTPA.' This standardized approach, endorsed by ESC and Choosing Wisely guidelines, reduces overuse of CTPA (which has risks: radiation, contrast-induced nephropathy, incidental findings requiring further workup, false-positive subsegmental PEs of uncertain significance).
Emergency physicians and ED nurses
Use the Revised Geneva Score as the first step in evaluating patients with suspected pulmonary embolism presenting to the ED with chest pain, dyspnea, or syncope. The score's objective criteria make it ideal for busy ED settings where multiple clinicians rotate through and consistency is essential. Calculate the score immediately upon patient arrival (while waiting for labs), then apply the validated diagnostic algorithm: low/intermediate probability → D-dimer first, high probability → direct to CTPA. This approach safely excludes PE in ~30–40% of patients without imaging, reducing radiation exposure, contrast use, and ED length of stay. Document the Revised Geneva Score in the ED chart to provide objective risk stratification for consultants and admitting teams.
Hospitalists and hospital medicine physicians
When hospitalized patients develop new dyspnea or chest pain, the Revised Geneva Score helps differentiate PE from other common causes (pulmonary edema, pneumonia, COPD exacerbation, anxiety). Hospitalized patients often have elevated D-dimer from coexisting conditions (sepsis, inflammation, post-operative state), reducing D-dimer's specificity—the Revised Geneva Score helps interpret positive D-dimer results in context. For example, a low Geneva score (0–3) + negative D-dimer safely excludes PE in a hospitalized patient. Conversely, a high Geneva score (≥11) in a post-operative cancer patient warrants direct imaging despite the D-dimer result. Use the score to have evidence-based discussions with radiology about CTPA appropriateness and to avoid unnecessary imaging in low-risk patients.
Pulmonologists and respiratory specialists
When consulted for suspected PE, use the Revised Geneva Score to validate the appropriateness of prior imaging or to guide further workup. If a patient already underwent CTPA without documented pretest probability assessment, calculate the Revised Geneva Score retrospectively to determine if the imaging was indicated—this is valuable for quality improvement and teaching. For patients with high Geneva scores and high-probability PE on CTPA (bilateral PEs, right heart strain), the score supports decisions about ICU admission, thrombolysis consideration, and aggressive anticoagulation. Use the score in multidisciplinary VTE conferences to standardize risk stratification and ensure adherence to evidence-based diagnostic pathways across the hospital.
Primary care physicians and outpatient providers
When a patient reports dyspnea or chest discomfort in the outpatient setting, the Revised Geneva Score helps decide whether to refer to the ED for urgent evaluation or pursue outpatient workup. A low Geneva score (0–3) in a young, otherwise healthy patient with atypical symptoms can guide outpatient D-dimer testing—if negative, PE is excluded and alternative diagnoses (musculoskeletal pain, anxiety, GERD) can be explored without ED referral. Conversely, an intermediate or high Geneva score, especially with concerning features (tachycardia, hemoptysis, unilateral leg swelling), warrants immediate ED referral for CTPA. Use the score to triage appropriately and avoid unnecessary ED visits for very low-risk patients while ensuring high-risk patients get urgent evaluation.
Hospital QI teams and radiology utilization committees
Incorporate the Revised Geneva Score into institutional PE diagnostic pathways to standardize pretest probability assessment and reduce inappropriate CTPA utilization. Create EHR-integrated clinical decision support tools that auto-calculate the Revised Geneva Score when a provider orders D-dimer or CTPA, prompting adherence to evidence-based algorithms (low/intermediate → D-dimer first, high → direct CTPA). Measure outcomes: CTPA utilization rates, positive CTPA yield (goal >15–20%), percentage of low-probability patients imaged without D-dimer (goal 0%), contrast-related adverse events, and missed PE cases. Many institutions have reduced CTPA ordering by 20–30% after implementing Geneva Score-based pathways, improving resource stewardship without increasing diagnostic failures. The objective nature of the Revised Geneva Score makes it particularly suitable for protocol-driven care.
Medical students, residents, and teaching faculty
Teach the Revised Geneva Score as the 'objective alternative' to the Wells PE score, highlighting the elimination of the subjective 'PE most likely diagnosis' criterion. Use this contrast to discuss inter-observer variability, evidence-based medicine, and clinical prediction rules. Quiz learners on the scoring: Which variables contribute the most points? (HR ≥95 = 5 points, unilateral edema + pain on palpation = 4 points each, prior VTE and unilateral pain = 3 points each). Why is heart rate stratified into two tiers (75–94 vs ≥95)? (Dose-response relationship between tachycardia and PE likelihood). Teach the diagnostic algorithm integration: low/intermediate probability + negative D-dimer excludes PE (>99% NPV), high probability → direct imaging. Use the Revised Geneva Score as a model for teaching structured clinical assessment, pretest probability estimation, and Bayesian reasoning in diagnostic decision-making.
The key advantage of the Revised Geneva Score over the Wells PE score is complete objectivity. Every variable is measurable or documentable: age (from the chart), previous VTE (from history), recent surgery/fracture (documented in records), active cancer (known diagnosis), heart rate (vital signs), unilateral symptoms (physical exam findings), hemoptysis (patient report + exam). There is NO equivalent to the Wells criterion 'PE is the most likely diagnosis' (3 points), which introduces significant subjectivity and inter-observer variability—studies show only moderate agreement (kappa ~0.5–0.6) between clinicians scoring the same patient with Wells PE. In contrast, the Revised Geneva has better inter-rater reliability (kappa ~0.7–0.8). This objectivity makes the Revised Geneva particularly valuable in academic centers with rotating residents and fellows, telemedicine consultations where the consultant hasn't examined the patient, and quality improvement initiatives requiring standardized risk stratification. If your institution struggles with inconsistent Wells PE scoring, consider adopting the Revised Geneva Score as the primary PE risk tool.
The Revised Geneva Score uniquely stratifies heart rate into two tiers: HR 75–94 bpm contributes 3 points, while HR ≥95 bpm contributes 5 points. This reflects the dose-response relationship between tachycardia and PE likelihood—higher heart rates correlate with larger clot burden, more hemodynamic compromise, and higher PE probability. A patient with HR 96 scores 5 points, while a patient with HR 90 scores 3 points—this 6-bpm difference can shift the overall score from intermediate to high probability (e.g., score 9 vs 11). Clinically, measure heart rate carefully and avoid 'rounding' (don't round HR 94 up to 95, or HR 99 down to 95—exact measurement matters). Also consider that heart rate can be influenced by pain, anxiety, fever, and beta-blockers. A young athlete on metoprolol may have HR 60 despite a large PE (scores 0 points for HR), while an anxious patient with chest wall pain may have HR 100 without PE (scores 5 points)—integrate the heart rate component with the full clinical picture rather than relying on it in isolation.
The Revised Geneva Score assigns significant points to unilateral lower limb findings: unilateral pain = 3 points, pain on palpation + edema = 4 points, unilateral edema = 4 points. These findings reflect the high likelihood of concurrent deep vein thrombosis (DVT), which co-occurs in approximately 40–50% of PE cases (though not always symptomatic). When a patient presents with suspected PE, ALWAYS examine both lower extremities systematically: look for asymmetric calf or thigh swelling (measure circumference if subtle), palpate the deep veins for tenderness (posterior tibial, popliteal, femoral), check for Homans sign (though insensitive). Document findings clearly: 'Left calf circumference 38 cm, right 35 cm (3 cm difference). Tenderness to palpation over left popliteal fossa. No erythema or warmth. Positive for unilateral pain (3 points) and unilateral edema (4 points).' If unilateral DVT symptoms are present, consider bilateral lower extremity Doppler ultrasound in addition to CTPA—finding DVT confirms VTE and may influence treatment decisions (e.g., IVC filter consideration if anticoagulation is contraindicated). Conversely, absence of leg symptoms (0 points for all three unilateral variables) suggests isolated PE without DVT, which is also common (~50–60% of PEs).
The Revised Geneva Score awards 2 points for 'active malignancy,' but what constitutes 'active' can be ambiguous. Use the standard VTE literature definition: cancer is considered active if the patient is (1) undergoing active treatment (chemotherapy, radiation, immunotherapy) within the past 6 months, (2) diagnosed within the past 6 months, or (3) has metastatic disease regardless of treatment status. Remote cancer history (e.g., breast cancer treated 10 years ago, now in remission) does NOT count as active malignancy—score 0 points. Conversely, a patient with metastatic lung cancer not currently on chemotherapy (palliative care only) still scores 2 points due to metastatic disease. Certain cancers are particularly high VTE risk: pancreatic, gastric, brain, ovarian, lung, hematologic malignancies. If uncertain whether cancer is 'active,' err on the side of scoring it as active (assign 2 points), as this increases pretest probability and ensures appropriate workup. Document clearly: 'Patient with stage IV colon cancer on active FOLFOX chemotherapy (cycle 8 two weeks ago)—scored as active malignancy, 2 points.'
When interpreting D-dimer results in conjunction with the Revised Geneva Score, remember that D-dimer has age-dependent specificity—it decreases with age due to baseline elevation from inflammation, comorbidities, and physiologic changes. The traditional D-dimer threshold (500 ng/mL) has excellent sensitivity (>95%) but poor specificity in older adults (often <10% in patients >70 years), leading to many false positives and unnecessary CTPA. To improve specificity without sacrificing safety, use age-adjusted D-dimer thresholds in patients >50 years old: **Age-adjusted threshold = Age (years) × 10 ng/mL** for patients >50. For example, a 68-year-old patient with Revised Geneva score 3 (low probability) and D-dimer 620 ng/mL: using the traditional threshold (500), D-dimer is positive → CTPA indicated. Using the age-adjusted threshold (68 × 10 = 680 ng/mL), D-dimer is NEGATIVE (620 < 680) → PE excluded, no CTPA needed. Age-adjusted D-dimer increases the proportion of low/intermediate Geneva score patients in whom PE can be safely excluded without imaging by ~10–15%, particularly in the elderly. This approach is endorsed by ESC PE guidelines and validated in multiple large studies (ADJUST-PE trial). Document clearly: 'D-dimer 620 ng/mL. Age-adjusted threshold for 68-year-old patient = 680 ng/mL. D-dimer negative by age-adjusted criteria. PE excluded.'
In high-probability patients (Revised Geneva ≥11), D-dimer testing is NOT recommended—proceed directly to CTPA. The rationale: (1) D-dimer has insufficient negative predictive value in high-probability patients (~85–90% NPV, not high enough to safely exclude PE). Missing even 10–15% of PEs in a high-risk population is unacceptable. (2) D-dimer is very likely to be positive in high-probability patients (>90% sensitivity), so a positive result doesn't add diagnostic information—you were already planning to image based on clinical probability. (3) Checking D-dimer delays definitive diagnosis and treatment initiation. For example, a patient with active pancreatic cancer (2 points) + prior DVT 2 years ago (3 points) + HR 108 (5 points) + left calf swelling (4 points) = Revised Geneva 14 (high probability). This patient should go directly to CTPA without D-dimer. Document: 'Revised Geneva Score 14 (high probability, ~70% PE prevalence). Per guidelines, proceeding directly to CTPA without D-dimer. Anticoagulation initiated empirically while awaiting imaging.' Some institutions have EHR hard stops that prevent D-dimer ordering when a high Geneva or Wells score is documented, ensuring adherence to evidence-based pathways and avoiding unnecessary testing.
Multiple head-to-head comparison studies show that the Revised Geneva Score and Wells PE score have comparable diagnostic accuracy for estimating PE probability (sensitivity ~85–90%, specificity ~40–50%, AUC ~0.75–0.80). Neither is definitively 'better'—the choice depends on your clinical context. **Use Revised Geneva when:** (1) You want to eliminate inter-observer variability (fully objective scoring). (2) You're implementing a standardized institutional pathway and need consistency. (3) You're in a teaching environment with rotating clinicians. (4) You're conducting research or quality improvement and need reproducible measurements. **Use Wells PE when:** (1) You value clinical gestalt and want the flexibility to override objective criteria with the 'PE most likely diagnosis' option. (2) Your institution has already adopted Wells PE and providers are familiar with it. (3) You're an experienced clinician comfortable with subjective probability estimation. Many EDs and hospitals use BOTH scores interchangeably, allowing clinicians to choose their preferred tool. What matters most is systematic pretest probability assessment (using any validated score) rather than unstructured clinical judgment alone, which is poorly calibrated and prone to bias.
The combination of low or intermediate Revised Geneva Score + negative D-dimer has a negative predictive value exceeding 99% for pulmonary embolism—meaning fewer than 1 in 100 patients in this category will have PE. This evidence-based threshold is considered safe for ruling out PE without imaging, endorsed by international guidelines (ESC, American College of Physicians, Choosing Wisely). For example: a 55-year-old patient with pleuritic chest pain, Revised Geneva score 4 (intermediate probability: age >65 = 0 points, no prior VTE, no surgery, no cancer, HR 88 = 3 points, no hemoptysis, no unilateral leg symptoms) and D-dimer 280 ng/mL (negative). PE is effectively excluded—discharge with reassurance and alternative diagnosis (musculoskeletal pain, viral pleurisy, anxiety). No CTPA needed. Document: 'Revised Geneva Score 4 (intermediate probability). D-dimer 280 ng/mL (negative). Combined low/intermediate Geneva + negative D-dimer has >99% NPV for PE. PE excluded. Diagnosis: musculoskeletal chest pain. Return precautions provided.' This approach safely avoids ~30–40% of CTPAs in suspected PE populations, reducing radiation exposure (especially important in young women of childbearing age), contrast-induced nephropathy, incidental findings requiring further workup, false-positive subsegmental PEs, and healthcare costs (~$1,500–2,500 per CTPA).
Hemoptysis (coughing up blood) contributes 2 points to the Revised Geneva Score and is considered a 'classic' PE symptom resulting from pulmonary infarction. However, it is present in only ~10–15% of PE cases, making it a highly SPECIFIC but very INSENSITIVE finding. Most patients with PE do NOT have hemoptysis—they present with dyspnea, chest pain, tachycardia, or syncope. When hemoptysis IS present, it raises PE probability significantly, but its absence does not lower probability much. Additionally, hemoptysis has a broad differential diagnosis: pulmonary infections (tuberculosis, pneumonia, bronchitis), lung cancer, bronchiectasis, mitral stenosis, trauma, anticoagulation-related bleeding. Always consider PE in the differential for hemoptysis (especially if accompanied by dyspnea and pleuritic chest pain), but also pursue alternative diagnoses if the Revised Geneva score is low and D-dimer is negative. Document clearly: 'Patient reports blood-streaked sputum × 2 days (scored as hemoptysis, 2 points). However, also has productive cough, fever, and left lower lobe infiltrate on CXR—pneumonia with hemoptysis more likely than PE. Revised Geneva 2 (low probability). D-dimer 220 ng/mL (negative). PE excluded. Treating community-acquired pneumonia.'
An emerging strategy to further optimize PE diagnosis is the YEARS algorithm, which combines simplified clinical criteria with D-dimer threshold adjustment. YEARS asks: (1) Is there clinical signs of DVT? (2) Is hemoptysis present? (3) Is PE the most likely diagnosis? If NONE of the three YEARS items are present, use a higher D-dimer threshold (1,000 ng/mL instead of 500 ng/mL) to exclude PE. If ≥1 item is present, use the standard 500 ng/mL threshold. The YEARS algorithm can be adapted to the Revised Geneva Score: if the Geneva score is LOW (0–3) and the patient has no DVT signs, no hemoptysis, and PE is not the most likely diagnosis, consider using the 1,000 ng/mL D-dimer threshold. This approach safely excludes PE in an additional 10–15% of patients compared to standard D-dimer threshold, reducing unnecessary CTPA. Example: 58-year-old with Revised Geneva 2 (age <65, HR 82, no other risk factors), D-dimer 680 ng/mL. Standard threshold: D-dimer positive → CTPA. YEARS-adapted threshold: no DVT signs, no hemoptysis, alternative diagnosis likely (anxiety) → use 1,000 ng/mL threshold → D-dimer negative (680 < 1,000) → PE excluded. The YEARS approach is still being validated but shows promise for resource stewardship in low-risk populations.
Your Revised Geneva Score estimates the clinical probability of pulmonary embolism (PE) using objective criteria. A score of 0–3 indicates low clinical probability (approximately 8% prevalence of PE in this group). A score of 4–10 indicates intermediate probability (~28% prevalence). A score of 11 or above indicates high probability (~74% prevalence). The simplified version uses a cutoff of 0–1 (low), 2–4 (intermediate), and ≥5 (high).
The key advantage of the Revised Geneva Score over the Wells PE score is that it relies entirely on objective variables — there is no subjective component equivalent to the Wells criterion of 'PE is the most likely diagnosis.' This makes it more reproducible across different clinicians and settings, though overall diagnostic performance is comparable between the two scoring systems.
Use the Revised Geneva Score when evaluating a patient with suspected pulmonary embolism to determine the appropriate diagnostic pathway. In low-probability patients, a negative D-dimer result can safely exclude PE without the need for CT pulmonary angiography (CTPA), reducing radiation exposure, contrast use, and healthcare costs. In intermediate-probability patients, D-dimer testing is also the first step; CTPA is pursued only if D-dimer is positive. In high-probability patients, proceed directly to CTPA, as D-dimer lacks sufficient negative predictive value in this group.
This score is particularly useful in settings where the Wells PE score may be less reliable due to inter-observer variability in the subjective criterion. It is endorsed by the European Society of Cardiology (ESC) guidelines for PE diagnosis and is appropriate for use in the emergency department, inpatient wards, and outpatient clinics.
The Revised Geneva Score was derived and validated predominantly in European populations presenting to the emergency department with suspected PE. Its performance may differ in populations with high prevalence of PE risk factors (e.g., post-surgical, oncology, or ICU patients) or in outpatient settings where the pretest probability spectrum differs.
Like all clinical prediction rules for PE, the Revised Geneva Score cannot definitively diagnose or exclude PE — it stratifies probability to guide further testing. The score does not account for all relevant risk factors; notably, oral contraceptive use, hormone replacement therapy, obesity, and thrombophilia are not included. The age criterion (>65) is a single binary variable that does not capture the gradient of risk with advancing age. Additionally, the score has not been extensively validated in pregnant patients, for whom PE diagnosis presents unique challenges and standard D-dimer thresholds do not apply.
For related assessments, see Wells Score (PE), Wells Score (DVT) and 4T Score (HIT).
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
Calculate the Wells Score to estimate the clinical probability of pulmonary embolism (PE). Guide decisions on CTPA and D-dimer testing.
EmergencyCalculate the Wells Score to assess the clinical probability of deep vein thrombosis (DVT). Guide diagnostic workup and D-dimer testing.
HematologyCalculate the 4T score for heparin-induced thrombocytopenia (HIT) pretest probability. Score ≤3: >99% NPV for HIT. Intermediate/High (≥4): stop heparin, start alternative anticoagulation.